Researcher undertaking experiment. Source: Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Chimeric Therapeutics (CHM) receives US patent for certain applications of its CAR T therapy
  • The patent covers certain applications of chimeric antigen receptor technology using chlorotoxin
  • The company says it is delighted to have patent protection granted in the largest global market for biopharmaceutical products
  • It follows a recent European patent grant, continuing the momentum for the company’s intellectual property portfolio underpinning its CLTX CAR pipeline assets
  • Shares have been trading 2.3 per cent higher at 22.5 cents at 11:45 am AEDT

Chimeric Therapeutics (CHM) has received a US patent for certain applications of its CAR T therapy.

The clinical stage cell therapy company is focused on the discovery, development and commercialisation of cell therapies.

It has developed CHM 1101 (CLTX CAR T) for the treatment of patients with solid tumours, which is being studied in a phase one clinical trial in recurrent, progressive glioblastoma.

A second CLTX CAR T phase one clinical trial is planned to begin this year in additional solid tumours.

Chimeric’s portfolio also includes the CORE-NK platform, a clinically validated, off the shelf natural killer (NK) cell therapy platform, which will aid the development of four new next generation NK and CAR NK assets with plans for phase one clinical trials to begin next year, in solid tumours and blood cancers.

Today, the company announced the United States Patent and Trademark Office issued a patent covering certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin, including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical-stage CAR NK asset CHM 1301.

Representing the largest global market for biopharmaceutical products, Chimeric’s CEO and Managing Director Jennifer Chow said the company is “delighted” to have patent protection granted for CLTX CAR therapies in the United States.

“The granting of this key US patent continues the momentum for the intellectual property portfolio underpinning our CLTX CAR pipeline assets, following the recent patent grant in Europe in September,” Ms Chow said.

Shares have been trading 2.3 per cent higher at 22.5 cents at 11:45 am AEDT.

CHM by the numbers
More From The Market Herald
IGO (ASX:IGO) - CEO & Managing DIrector, Peter Bradford

" IGO (ASX:IGO) produces first battery-grade lithium hydroxide from Kwinana refinery

IGO (ASX:IGO) has produced the first battery-grade lithium hydroxide from the Kwinana Lithium Hydroxide Refinery in…

" Seafarms (ASX:SFG) appoints Rod Dyer as CEO among executive changes

Seafarms (ASX:SFG) has appointed Rod Dyer as CEO, effectively immediately.
Recce Pharmaceuticals (ASX:RCE) - Chief Executive Officer, James Graham

" Recce Pharmaceuticals’ (ASX:RCE) clinical trial returns positive safety profile

Recce Pharmaceuticals (ASX:RCE) has seen its clinical trial receive a good safety profile among ten healthy…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…